Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.
about
Developments in the treatment of hemophilia B: focus on emerging gene therapyScalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production.Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trialSystemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liverAn AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse modelsProgress and challenges in viral vector manufacturingAdvanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation Sequencing.Immune responses to AAV vectors: overcoming barriers to successful gene therapyCapsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.Transient transfection methods for clinical adeno-associated viral vector production.Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations.Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms.Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system.OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA.OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA.Molecular design for recombinant adeno-associated virus (rAAV) vector production.Design and Development of AAV-based Gene Supplementation Therapies for Achromatopsia and Retinitis Pigmentosa.Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment.Pharmacology of Recombinant Adeno-associated Virus Production.
P2860
Q26823376-3DB69307-02BC-4E41-8B46-7436421336D5Q33555259-9555FC6E-39FC-481D-AAB7-E09F64CC322AQ33976906-FF54181B-E83B-480C-938C-85F3A73EC115Q34069571-7AFFAE7D-F21C-4A08-9D45-53252FC6C073Q34621723-851F747F-0CE5-4853-B261-8311AAB45200Q34770593-826BCA6D-5316-4965-84BA-E056CACAF677Q34843808-3F677CE8-6A8C-4F80-8820-33AD88DA9472Q34843835-C72C377E-35A4-467F-BA28-1281FA6F2E23Q35184184-6ED06260-770D-4F71-9863-30648A60351EQ36713761-893DDB1E-41E6-44F7-A51A-A4D9EAB1C128Q36939744-C9D24FD8-341A-4069-A3E4-A10B42075BCEQ36983740-3D4A4A9A-7CD9-4A68-AE21-173AC707AA72Q37209197-36D4118B-8B8E-4B40-AE0D-25FBAB223FCCQ37348229-6B077FC4-332C-4333-B449-FC5013CF52F3Q37479802-705C822E-F963-46DE-8A49-8E581C7BADF5Q37686976-DB679398-15A8-435E-9F62-D2AB706EB1F3Q38717682-598753BA-47DF-424A-8628-1B8C7074485FQ38776037-0D8EED4B-0BB9-4851-9C20-551C87664598Q38993966-2014A47A-0CF9-4F21-8F25-600D87A1B03CQ39126013-4EFF8E65-9393-43C5-830E-A51E243FEF10Q39553052-377CB196-FE17-4792-ABCD-602A23F3346DQ39674124-46E8B368-B2CC-427A-AAF3-68FE959F5E86Q40357060-B11FB98B-8560-41A7-874E-96882DD53FB0Q40560600-B9117916-A2E5-46D3-9D26-AFF3B72722E8Q45323804-AD4A04ED-BDD7-4F68-804A-58E0FC158C31Q45875179-2636E90D-6E92-4277-91B7-6E86555E38ACQ50977887-1CF2C95B-44D4-4585-9156-01DB4E7AB0A4Q52717185-DE3ADE36-49C9-4455-80B1-9B555A2F2F97
P2860
Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Undetectable transcription of ...... ed capsid in immune responses.
@en
Undetectable transcription of ...... ed capsid in immune responses.
@nl
type
label
Undetectable transcription of ...... ed capsid in immune responses.
@en
Undetectable transcription of ...... ed capsid in immune responses.
@nl
prefLabel
Undetectable transcription of ...... ed capsid in immune responses.
@en
Undetectable transcription of ...... ed capsid in immune responses.
@nl
P2093
P2860
P356
P1433
P1476
Undetectable transcription of ...... ed capsid in immune responses.
@en
P2093
Bernd Hauck
Federico Mingozzi
J Fraser Wright
Jürg M Sommer
Katherine A High
Olga Zelenaia
Peter H Smith
Samuel L Murphy
Xingge Liu
P2860
P304
P356
10.1038/MT.2008.227
P577
2008-10-21T00:00:00Z